---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-110548"
form_type: "8-K"
ticker: "ANVS"
cik: "0001477845"
company_name: "Annovis Bio, Inc."
filed_at: "2025-11-13T23:59:59+00:00"
generated_at: "2026-05-16T20:18:38.237484+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Annovis Bio reports Q3 net loss of $0.37/share; Phase 3 AD trial fully activated at 84 sites

## Summary
- Cash and equivalents $15.3M as of Sep 30, 2025; plus $9.4M in Oct offerings.
- Phase 3 early AD study (NCT06709014) fully activated; first patients completed 6-month treatment.
- Biomarker results from Phase 2/3 showed reductions in neuroinflammation and neurodegeneration markers.
- Appointed Mark Guerin as CFO; all patents transferred to new crystal form of buntanetap (IP through 2046).
- R&D expense $6.3M (up from $2.7M YoY); net loss $0.37 per share (vs $0.97).

## SEC filing metadata
- accession: 0001104659-25-110548
- form_type: 8-K
- ticker: ANVS
- cik: 0001477845
- company_name: Annovis Bio, Inc.
- filed_at: 2025-11-13T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1477845/000110465925110548/0001104659-25-110548-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1477845/000110465925110548/anvs-20251112x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-110548
- JSON: https://secwatch.observer/filing/0001104659-25-110548.json
- Plain text: https://secwatch.observer/filing/0001104659-25-110548.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.